* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, reportedits lead integrase inhibitor, Zintevir (AR177), displayed excellentsafety results in both animal studies and Phase I trials at doses thatshow anti-HIV activity in vitro. Data were presented in two papers inthe September issue of the Journal of Pharmacology andExperimental Therapeutics.

* BTG USA Inc., of Gulph Mills, Pa., signed an exclusive licenseagreement granting GenVec Inc., of Rockville, Md., rights to developgene delivery systems based on BTG's herpes simplex virustechnology. GenVec will develop systems for delivering genes to thebrain. Financial terms were not disclosed.

* Cytoclonal Pharmaceutics Inc., of Dallas, obtained an exclusiveworldwide license to antisense technology developed at theUniversity of Texas at Dallas. The licensed technology wasdeveloped by Donald Gray, professor of molecular and cell biologyat the university, who identified optimum regions within genes tobind antisense products.

* Incyte Pharmaceuticals Inc., of Palo Alto, Calif., signed a broad-based genomics and software license agreement with Monsanto Co.,of St. Louis, to generate sequence and expression data from certainplant species, including corn. Incyte said the deal marked its entryinto plant genomics and the first deal in which it licensed itsLifeTools software as a stand-alone product. Terms were notdisclosed.

* Ligand Pharmaceuticals Inc., of San Diego, said its board adopted ashareholders rights plan. The move was not made in response to anytakeover attempt, the company said.

* MDS Health Group Ltd., of Toronto, through its Panlabs operationand in cooperation with St. Louis-based Tripos Inc., signed a $1.5million agreement with Bristol-Myers Squibb Co., of New York, todevelop new drug leads in a broad range of therapeutic areas.

* Neurobiological Technologies Inc., of Richmond, Va., said resultsof a pilot Phase II trial of the peptide Dynorphin A indicate patientsreceiving the drug required substantially less morphine than placebopatients to manage post-surgical pain. Patients were free to self-administer morphine following hip or knee replacement surgery. Themedian total morphine used by placebo patients was 44 percentgreater than Dynorphin A.

(c) 1997 American Health Consultants. All rights reserved.

No Comments